Article
Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer.
Cancer research - 1 Apr 2001
Senekowitsch-Schmidtke R, Schuhmacher C, Becker K F, Nikula T K, Seidl C, Becker I, Miederer M, Apostolidis C, Adam C, Huber R, Kremmer E, Fischer K, Schwaiger M
Abstract excerpt
A monoclonal antibody (E-cadherin delta 9-1) directed against a characteristic E-cadherin mutation (in-frame deletion of exon 9), found in diffuse-type gastric cancer but not in any normal tissue, was conjugated with the high linear energy transfer alpha-emitter 213Bi and tested for its binding specificity in s.c. and i.p. nude mice tumor models. After intratumoral application in s.c. tumors expressing mutant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.